Overview

A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma (LEAP)

Status:
Completed

Trial end date:
2013-06-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine whether CO-1.01 is safe and effective in the treatment of patients with metastatic pancreatic cancer and low hENT1 expression compared with gemcitabine.

Phase:

Phase 2

Details

Lead Sponsor:

Clovis Oncology, Inc.

Treatments:

Gemcitabine